May 17, 2007
Gilead Sciences' Chief Operating Officer and Chief Financial Officer Establishes Rule 10b5-1 Stock Trading Plan
Commencing in June 2007, Dr. Milligan's plan provides for the exercise and sale of up to 30,000 stock options each quarter on pre-determined dates through December 2009.
The transactions under the plan are disclosed publicly through Form 144 and Form 4 filings with the Securities and Exchange Commission. James M. Denny and Paul Berg, PhD, members of Gilead's Board of Directors, John C. Martin, PhD, President and Chief Executive Officer and a member of Gilead's Board of Directors, and Gregg H. Alton, Senior Vice President and General Counsel, also maintain stock trading plans under Rule 10b5-1, and other officers and directors of the company may do so in the future.
Rule 10b5-1 allows insiders to adopt written plans for trading securities in a non-discretionary, pre-scheduled manner in order to avoid concerns about initiating stock transactions when the insider may be aware of non-public information. Such plans also allow insiders to diversify their holdings and to minimize the market effect of stock sales by spreading them out over time.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).
SOURCE: Gilead Sciences, Inc.
Gilead Sciences, Inc.
Susan Hubbard, Investors, 650-522-5715
Amy Flood, Media, 650-522-5643